Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

TC Biopharm (Holdings) Plc (TCBP)

0.385   0.004 (1.05%) 09-27 15:58
Open: 0.381 Pre. Close: 0.381
High: 0.4099 Low: 0.38
Volume: 109,640 Market Cap: 3(M)

Technical analysis

as of: 2023-09-27 4:22:26 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 0.62     One year: 0.75
Support: Support1: 0.34    Support2: 0.29
Resistance: Resistance1: 0.53    Resistance2: 0.64
Pivot: 0.45
Moving Average: MA(5): 0.39     MA(20): 0.47
MA(100): 0.6     MA(250): 3.5
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 10.4     %D(3): 9.1
RSI: RSI(14): 32.8
52-week: High: 15.5  Low: 0.34
Average Vol(K): 3-Month: 665 (K)  10-Days: 140 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TCBP ] has closed above bottom band by 11.8%. Bollinger Bands are 37.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.41 - 0.41 0.41 - 0.42
Low: 0.37 - 0.38 0.38 - 0.38
Close: 0.38 - 0.38 0.38 - 0.38

Company Description

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Headline News

Wed, 27 Sep 2023
TC BioPharm to Present at the LD Micro Main Event XVI - WV News

Wed, 27 Sep 2023
TC BioPharm to Present at the LD Micro Main Event XVI - PR Newswire

Tue, 05 Sep 2023
TC BioPharm Announces Grant Funding in Collaboration with ... - PR Newswire

Tue, 29 Aug 2023
Why Alpha Tau Medical Shares Are Trading Higher By Over 8 ... - UK

Tue, 29 Aug 2023
TC BioPharm to Present at H.C. Wainwright 25th Annual Global ... - PR Newswire

Mon, 31 Jul 2023
TC BioPharm Maintains Nasdaq Listing - TC BioPharm (Holdings) (NASDAQ:TCBP) - Benzinga

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 7 (M)
Shares Float 2 (M)
% Held by Insiders 11.7 (%)
% Held by Institutions 5.2 (%)
Shares Short 35 (K)
Shares Short P.Month 88 (K)

Stock Financials

EPS -2.2
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.03
Profit Margin (%) -36.2
Operating Margin (%) -310.1
Return on Assets (ttm) -78.6
Return on Equity (ttm) 0
Qtrly Rev. Growth 188.6
Gross Profit (p.s.) 0.52
Sales Per Share 0.52
EBITDA (p.s.) -1.54
Qtrly Earnings Growth 0
Operating Cash Flow -15 (M)
Levered Free Cash Flow -8 (M)

Stock Valuations

PE Ratio -0.18
PEG Ratio 0
Price to Book value -12.71
Price to Sales 0.72
Price to Cash Flow -0.2

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.